OGN — Organon & Co · catalysts, narrative & risks

Organon & Co. (NYSE: OGN) — Research Snapshot as of 2026-10-28

Context

Organon is a global pharmaceutical company spun off from Merck (known as MSD outside the U.S.), focused on women's health, biosimilars, and established/off-patent brands, headquartered in Jersey City, NJ [2], [21], [24]. It trades at roughly $13.77 on October 28, 2026, with a market capitalization of $3.6B, and has been trading at the top of its 52-week range ($5.69–$13.83) after roughly a +96% total return over the past 12 months [6], [10], [19], [20].

---

1. Recent Catalysts (last ~1–3 months)